BioNTech Results Presentation Deck

Comparison Guidance To Actuals 2021 Financial Year COVID-19 vaccine revenues 28 R&D expenses SG&A expenses Capital expenditures Guidance as of Nov 2021 € 16 - 17 bn € 950 1,050 m € 250 - 300 m € 175 - 225 m Actual result FY 2021 € 19 bn € 950 m € 340 m € 180 m Please refer to the Annual Report on Form 20-F for the year ended December 31, 2021 for further details.. HIC, high-income countries ● ● Drivers ~2.6bn doses delivered in 2021 vs. up to 2.5bn doses guided Higher proportion of doses than estimated delivered to HIC -40% related to COVID-19 vaccine clinical program Increase through organic and inorganic growth of organization Investment in infrastructure and COVID-19 vaccine production capacity BIONTECH

View entire presentation